Weiguo Zhai, a former senior director at AstraZeneca Pharmaceuticals, has agreed to settle SEC insider trading charges related to trading in Icosavax Inc. stock ahead of the company’s acquisition by AstraZeneca. The SEC filed the settled complaint on July 8, 2026, in the District of Maryland, alleging Zhai misappropriated confidential information and realized $10,006 in illicit profits.
What happened
The SEC charged Zhai with violating Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, the antifraud provisions that prohibit trading on material nonpublic information. The commission also charged him with violating Section 14(e) and Rule 14e-3, which specifically address trading in the context of tender offers.
The complaint alleged that Zhai was on AstraZeneca’s due diligence team evaluating the anticipated acquisition of Icosavax Inc. through a tender offer. He allegedly misappropriated confidential information about the planned transaction and traded on that nonpublic information for personal benefit.
Key facts
| Item | Details |
|---|---|
| Defendant | Weiguo Zhai, age 56, Potomac, MD |
| Employer | AstraZeneca Pharmaceuticals LP |
| Target company | Icosavax Inc. |
| Shares purchased (own account) | 1,000 shares at $11.04 |
| Shares purchased (wife’s account) | 1,000 shares at $10.54 |
| Illicit profits | $10,006 |
| Disgorgement | $10,006 |
| Prejudgment interest | $1,535 |
| Civil penalty | $10,006 |
| Total settlement | $21,547 |
| Stock price increase post-announcement | 49.48% |
Icosavax impact
Zhai worked at AstraZeneca Pharmaceuticals LP, a wholly owned subsidiary of AstraZeneca PLC, from July 2020 to May 2024. He was based in the Gaithersburg, Maryland office and served as a senior director for research and development.
The SEC said Zhai was assigned to AstraZeneca’s due diligence team evaluating the anticipated acquisition of Icosavax, a biopharmaceutical company focused on vaccine development. The acquisition was announced on December 12, 2023, with a reported deal value of approximately $800 million.
According to the complaint, Zhai purchased 1,000 shares of Icosavax in his own brokerage account at $11.04 per share and another 1,000 shares in his wife’s account at $10.54 per share. After the acquisition announcement caused Icosavax stock to rise approximately 49.48%, Zhai sold the shares on December 12 and 13, 2023, realizing aggregate illicit profits of $10,006.
What investors should do
Insider trading undermines market integrity and harms ordinary investors who trade without access to material nonpublic information. The SEC’s charges against Zhai illustrate how employees with access to confidential deal information can exploit that advantage for personal gain.
The SEC emphasized that Zhai consented to the entry of a final judgment permanently enjoining him from future violations of the charged provisions. The settlement is subject to court approval and was reached without Zhai admitting or denying the allegations.
How to recover your losses
Investors who traded Icosavax stock during the relevant period may wish to review their account records for potential claims. While the SEC’s enforcement action addresses the illegal trading itself, private securities litigation and FINRA arbitration may provide avenues for affected investors to seek compensation.
Documenting the timing of trades, the prices paid, and any information known at the time of trading is essential for evaluating potential recovery options. Investors should consult a qualified securities attorney to assess their specific circumstances.
Haselkorn & Thibaut fights for investor recovery
Haselkorn & Thibaut is a securities law firm founded by former Wall Street defense attorneys who shifted their practice to represent investors. The firm has recovered over $520 million for clients in securities matters and maintains a 98 percent success rate in resolved nontraded REIT cases. Attorneys are AV Preeminent rated through Martindale-Hubbell, designated as Super Lawyers, and hold a 5.0-star client review average. The firm operates on a contingency basis — no recovery, no fee.
Contact Haselkorn & Thibaut today
Time matters in recovery cases. The earlier you act, the stronger your position. The firm offers a free case evaluation to assess your losses, review your account history, and explain your options under arbitration or settlement.
- Main Phone: 1-888-885-7162
- website for a free consultation
Offices in Florida, New York, Arizona, Texas, and North Carolina. Former Wall Street defense attorneys with 95+ years of combined experience. No recovery, no fee.
This article is for informational purposes only and does not constitute legal advice. Investors should consult a qualified securities attorney to discuss their specific situation.
